<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03380845</url>
  </required_header>
  <id_info>
    <org_study_id>2017P002061</org_study_id>
    <nct_id>NCT03380845</nct_id>
  </id_info>
  <brief_title>Comparison of 1,550-nm Laser and Fractional Radiofrequency Microneedle for the Treatment of Acne Scars in Ethnic Skin</brief_title>
  <official_title>Comparison of Fractional Erbium-Doped 1,550-nm Laser and a Bipolar Fractional Radiofrequency Microneedle Device for the Treatment of Atrophic Acne Scars in Ethnic Skin: A Randomized Split-Face Controlled Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Society for Dermatologic Surgery</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this randomized, split-face, controlled study is to compare the&#xD;
      efficacy and safety of a erbium-doped 1,550-nm non-ablative fractional laser and a bipolar&#xD;
      fractional radiofrequency microneedle device for the treatment of atrophic facial acne scars&#xD;
      in ethnic skin (Fitzpatrick Skin Phototypes III-VI).&#xD;
&#xD;
      The hypothesis of this study is that both erbium-doped 1,550-nm non-ablative fractional laser&#xD;
      and the bipolar fractional radiofrequency microneedle device are equally effective for the&#xD;
      treatment of atrophic acne scars in ethnic skin (SPT III-VI). However, the bipolar fractional&#xD;
      radiofrequency microneedle device has less adverse effects than erbium-doped 1,550-nm&#xD;
      non-ablative fractional laser due to the absence of scattering and the absence of&#xD;
      chromophore-specific targets - predominantly melanin - traditionally needed with laser&#xD;
      treatments; hence the fractional radiofrequency microneedle device will have a higher safety&#xD;
      profile in darker skin types .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne is a highly prevalent disease and post-acne scaring has shown to have detrimental&#xD;
      effects on a person's physical, mental, and social well-being. Acne scars can be divided in&#xD;
      general categories of hypertrophic or keloid scars, atrophic scars (icepick, rolling,&#xD;
      boxcar), and pigmentation alterations (redness, hypo and hyper-pigmentation). This study will&#xD;
      focus on treatment of moderate to severe grades of atrophic acne scarring. Our aim is to&#xD;
      compare the efficacy and safety of a erbium-doped 1,550-nm non-ablative fractional laser and&#xD;
      a bipolar fractional radiofrequency microneedle device for the treatment of atrophic acne&#xD;
      scars in ethnic skin (Fitzpatrick Skin Phototypes III-VI) by performing a split-face&#xD;
      randomized controlled trial.&#xD;
&#xD;
      Both devices in this study are already FDA approved treatment modalities for acne scarring.&#xD;
&#xD;
      History of erbium-doped 1,550-nm non-ablative fractional laser (FraxelÂ® Restore Laser System,&#xD;
      Solta Medical, Inc., Hayward, CA):&#xD;
&#xD;
      Non-ablative fractional lasers work via the theory of fractional photothermolysis, which&#xD;
      creates hundreds to thousands of microscopic thermal zones (MTZs), or columns of thermally&#xD;
      injured skin, while sparing the surrounding tissue. The pixilated nature of treatment and the&#xD;
      functionally unimpaired stratum corneum allow for rapid tissue healing and allows for safer&#xD;
      treatments of our patients. Mechanistically, fractional photothermolysis allows controlled&#xD;
      amounts of high energy to be delivered deep within the dermis resulting in collagenolysis and&#xD;
      neocollagenesis, which smoothes the textural abnormalities of acne scarring.&#xD;
&#xD;
      Multiple published studies have demonstrated that erbium-doped 1,550-nm non-ablative&#xD;
      fractional laser (&quot;NAFL&quot;) can be successfully utilized in the treatment of all forms of&#xD;
      atrophic acne scarring - ice-pick, boxcar, and rolling scars - with a very favorable safety&#xD;
      profile in all skin types, and thus, has been cleared by Food and Drug Administration (FDA)&#xD;
      for that particular indication. According to the manufacture manual (reference attached in&#xD;
      the &quot;Attachments&quot; section), NAFL is indicated for &quot;use in skin resurfacing procedures as well&#xD;
      as treatment of acne scars, surgical scars, lentigos (age spots), solar lentigos (sun spots),&#xD;
      actinic keratosis, and melasma.&quot;&#xD;
&#xD;
      History of the fractional radiofrequency microneedle device (Fractora; Invasix Ltd./InMode MD&#xD;
      Ltd., Israel):&#xD;
&#xD;
      Fractional radiofrequency is not a laser. Instead, these devices use an array of electrodes&#xD;
      that allows for zones of thermal wounds to be created between areas of unaffected zones, thus&#xD;
      stimulating dermal remodeling and allowing for a supply of reservoir cells to promote&#xD;
      healing. Variations of fractional radiofrequency exist that employ microneedles to deliver&#xD;
      electrical current to a particular depth within the dermis that decreases damage to the&#xD;
      epidermis. These fractional radiofrequency microneedle devices provide an alternative to&#xD;
      conventional methods of acne-scar treatment (such as NAFL). Great interest has been&#xD;
      culminating over the recent years for the use of such devices in acne scars due to the&#xD;
      absence of light scattering and the absence of chromophore-specific targets traditionally&#xD;
      needed with laser treatments. As melanin is not a target, it is felt to have a higher safety&#xD;
      profile in darker skin phototypes.&#xD;
&#xD;
      A recent study investigated the safety and efficacy of a specific bipolar fractional&#xD;
      radiofrequency microneedle device (Fractora; Invasix Ltd./InMode MD Ltd., Israel) for acne&#xD;
      and acne scarring. In this study, 8 patients with acne scars were reported and it was noted&#xD;
      that all patients (regardless of their skin phototypes) had improvement in their active acne&#xD;
      and acne scars after 4 treatments and a 1 month, on average follow-up period. The treatment&#xD;
      was well tolerated without any side-effects. Skin biopsies from this study showed reduction&#xD;
      in scar depth and new collagen formation with an increase in elastic fibers and adnexal&#xD;
      structures noted. A follow-up report showed that 4 out of 8 patients who were in the original&#xD;
      study returned for a long term follow-up from 1 to 2 years, that showed ongoing clinical&#xD;
      improvements in these patients. This specific bipolar fractional radiofrequency microneedle&#xD;
      (&quot;FRM&quot;) device has been FDA-approved for acne scars and skin rejuvenation.&#xD;
&#xD;
      To this date the efficacy and safety of 1,550-nm fractionated photothermolysis system has not&#xD;
      been compared to a fractional radiofrequency microneedle device for atrophic acne scars in&#xD;
      ethnic skin in a randomized split-face controlled trial. A major advantage of a split-face&#xD;
      self-controlled design would be to minimize any confounding factors. Laser resurfacing has&#xD;
      been well studied and is widely used in individuals with fair skin - Fitzpatrick skin&#xD;
      phototypes (SPT) I to II. However, there is a paucity of published studies involving&#xD;
      individuals with darker skin types (SPT III-VI)-a population that has a higher risk of&#xD;
      laser-associated dyspigmentation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Actual">October 30, 2018</completion_date>
  <primary_completion_date type="Actual">October 30, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Randomized split-face clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment</measure>
    <time_frame>three months after last treatment</time_frame>
    <description>Improvement in acne scarring will be measured by two blinded evaluators both by in-person assessments and by photographic review (digital photography will be used under standardized conditions). A quartile grading scale (1 = 1% to 25%, 2 =26% to 50%, 3 =51% to 75%, 4 = &gt;76% improvement) will be used to measure acne scar improvement. Higher score means better outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparing Side Effects of the Different Lasers</measure>
    <time_frame>treatment visit 1, treatment visit 2, treatment visit 3, three months after last treatment</time_frame>
    <description>measure side effects by patient reported adverse events and blinded physician assessment of adverse effects. Parameters, include erythema, edema, blistering, crusting, scarring, hypopigmentation, and hyperpigmentation, will be graded on a 4-point scale (0 = absent, 1= mild, 2 = moderate, and 3 = severe). Higher score means worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparing Intensity of Pain With the Different Lasers</measure>
    <time_frame>treatment visit 1, treatment visit 2, treatment visit 3</time_frame>
    <description>Patients will also be evaluated the intensity of pain using a visual analogue scale (0 = absence of pain, 10 = most-severe pain). Higher score means worse outcome</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Acne Scars</condition>
  <arm_group>
    <arm_group_label>Fraxel Restore on one side of the face</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fraxel Restore on one side of the face&#xD;
Fraxel Restore: acne scar correction&#xD;
Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fractora on the other side of the face</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fractora on the other side of the face&#xD;
Fractora: acne scar correction&#xD;
Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fraxel Restore</intervention_name>
    <description>Non-ablative Laser. In the study, one side of the face will be treated with Fraxel Restore monthly for three months.</description>
    <arm_group_label>Fraxel Restore on one side of the face</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fractora</intervention_name>
    <description>Fractional Radiofrequency Microneedling Device. In the study, one side of the face will be treated with Fractora monthly for three months.</description>
    <arm_group_label>Fractora on the other side of the face</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women with Fitzpatrick skin types III through VI and facial acne scarring of&#xD;
             grades III-IV will be enrolled. Both sides of the participants' face should have&#xD;
             almost similar amount and severity of acne scarring. Participants will be over 18&#xD;
             years old&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients have to be overall healthy without a history of keloidal scarring, localized&#xD;
             or active infection in the treatment region, immunodeficiency disorders, porphyria or&#xD;
             light sensitivity, and connective tissue disorders. Per PI discretion, any serious&#xD;
             medical condition that may interfere with the study. In addition, pregnant or nursing&#xD;
             women, patients who have been taking isotretinoin for a period of 6 months before&#xD;
             treatment, and patients who have received any cosmetic treatment (lasers,&#xD;
             dermabrasion, chemical peels, etc) in the previous 6 months will be excluded. Also,&#xD;
             patients with renal disease, and any allergies to Lidocaine, Tetracaine, or Valtrex&#xD;
             will be excluded.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mathew Avram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>MGH</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Purvis D, Robinson E, Merry S, Watson P. Acne, anxiety, depression and suicide in teenagers: a cross-sectional survey of New Zealand secondary school students. J Paediatr Child Health. 2006 Dec;42(12):793-6.</citation>
    <PMID>17096715</PMID>
  </reference>
  <reference>
    <citation>Manstein D, Herron GS, Sink RK, Tanner H, Anderson RR. Fractional photothermolysis: a new concept for cutaneous remodeling using microscopic patterns of thermal injury. Lasers Surg Med. 2004;34(5):426-38.</citation>
    <PMID>15216537</PMID>
  </reference>
  <reference>
    <citation>Alster TS, Tanzi EL, Lazarus M. The use of fractional laser photothermolysis for the treatment of atrophic scars. Dermatol Surg. 2007 Mar;33(3):295-9.</citation>
    <PMID>17338686</PMID>
  </reference>
  <reference>
    <citation>Chrastil B, Glaich AS, Goldberg LH, Friedman PM. Second-generation 1,550-nm fractional photothermolysis for the treatment of acne scars. Dermatol Surg. 2008 Oct;34(10):1327-32. doi: 10.1111/j.1524-4725.2008.34284.x.</citation>
    <PMID>19040687</PMID>
  </reference>
  <reference>
    <citation>Mahmoud BH, Srivastava D, Janiga JJ, Yang JJ, Lim HW, Ozog DM. Safety and efficacy of erbium-doped yttrium aluminum garnet fractionated laser for treatment of acne scars in type IV to VI skin. Dermatol Surg. 2010 May;36(5):602-9. doi: 10.1111/j.1524-4725.2010.01513.x. Epub 2010 Apr 1.</citation>
    <PMID>20384757</PMID>
  </reference>
  <reference>
    <citation>Alexis AF, Coley MK, Nijhawan RI, Luke JD, Shah SK, Argobi YA, Nodzenski M, Veledar E, Alam M. Nonablative Fractional Laser Resurfacing for Acne Scarring in Patients With Fitzpatrick Skin Phototypes IV-VI. Dermatol Surg. 2016 Mar;42(3):392-402. doi: 10.1097/DSS.0000000000000640.</citation>
    <PMID>26945321</PMID>
  </reference>
  <reference>
    <citation>Hruza G, Taub AF, Collier SL, Mulholland SR. Skin rejuvenation and wrinkle reduction using a fractional radiofrequency system. J Drugs Dermatol. 2009 Mar;8(3):259-65.</citation>
    <PMID>19271373</PMID>
  </reference>
  <reference>
    <citation>Chandrashekar BS, Sriram R, Mysore R, Bhaskar S, Shetty A. Evaluation of microneedling fractional radiofrequency device for treatment of acne scars. J Cutan Aesthet Surg. 2014 Apr;7(2):93-7. doi: 10.4103/0974-2077.138328.</citation>
    <PMID>25136209</PMID>
  </reference>
  <reference>
    <citation>Chae WS, Seong JY, Jung HN, Kong SH, Kim MH, Suh HS, Choi YS. Comparative study on efficacy and safety of 1550 nm Er:Glass fractional laser and fractional radiofrequency microneedle device for facial atrophic acne scar. J Cosmet Dermatol. 2015 Jun;14(2):100-6. doi: 10.1111/jocd.12139. Epub 2015 Mar 23. Erratum in: J Cosmet Dermatol. 2016 Sep;15(3):303.</citation>
    <PMID>25810322</PMID>
  </reference>
  <reference>
    <citation>Abdel Hay R, Shalaby K, Zaher H, Hafez V, Chi CC, Dimitri S, Nabhan AF, Layton AM. Interventions for acne scars. Cochrane Database Syst Rev. 2016 Apr 3;4:CD011946. doi: 10.1002/14651858.CD011946.pub2. Review.</citation>
    <PMID>27038134</PMID>
  </reference>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 8, 2017</study_first_submitted>
  <study_first_submitted_qc>December 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2017</study_first_posted>
  <results_first_submitted>October 26, 2019</results_first_submitted>
  <results_first_submitted_qc>November 17, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2019</results_first_posted>
  <last_update_submitted>November 17, 2019</last_update_submitted>
  <last_update_submitted_qc>November 17, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Mathew Avram, MD, JD</investigator_full_name>
    <investigator_title>Director, MGH Laser, Cosmetic and Dermatologic Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03380845/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bilateral Facial Treatment With Fraxel and Fractora</title>
          <description>Randomized treatment with Fraxel on one side of the face, and Fractora on the opposite side of the face - the study is a randomized, split-face study in subjects seeking facial acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4">Participants got bilateral face treatments with Fraxel on one side of face; Fractora on the other.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face.</population>
      <group_list>
        <group group_id="B1">
          <title>Split Face Study Bilateral Fraxel Restore vs Fractora</title>
          <description>Randomized treatment with Fraxel Restore on one side of the face, and Fractora on the opposite side of the face - the study is a randomized,single-center, split-face study in subjects seeking acne scar correction. Subjects were treated with Fraxel on one side of the face and Fractora on the other side of the face. The side of the face for each device was randomly assigned.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="4"/>
          </count_list>
        </analyzed>
        <analyzed>
          <units>side of the face treated</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="18" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type (FST) Classification</title>
          <description>FST Type I skin always burns, never tans (pale white; blond or red hair; blue, gray eyes; freckles) FST Type II skin usually burns, tans minimally (white; blond, brown or red hair; blue, green, or hazel eyes) FST Type III skin sometimes has a mild burn, tans uniformly (cream white; yellowish; any hair color or brown eyes) FST Type IV skin burns minimally, always tans well (light brown; olive; dark brown to black hair) FST Type V skin very rarely burns, tans very easily (brown) FST Type VI skin never burns, always tans (deeply pigmented dark brown to darkest brown, black in complexion)</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <units_analyzed>Participants</units_analyzed>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>FST III</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>FST VI</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment</title>
        <description>Improvement in acne scarring will be measured by two blinded evaluators both by in-person assessments and by photographic review (digital photography will be used under standardized conditions). A quartile grading scale (1 = 1% to 25%, 2 =26% to 50%, 3 =51% to 75%, 4 = &gt;76% improvement) will be used to measure acne scar improvement. Higher score means better outcome.</description>
        <time_frame>three months after last treatment</time_frame>
        <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
        <group_list>
          <group group_id="O1">
            <title>Fraxel Restore on One Side of the Face</title>
            <description>Fraxel Restore on one side of the face for acne scar correction</description>
          </group>
          <group group_id="O2">
            <title>Fractora on Other Side of the Face</title>
            <description>Fractora on other side of the face for acne scar correction</description>
          </group>
        </group_list>
        <measure>
          <title>Improvement in Acne Scarring - From Baseline to Three Months After Last Treatment</title>
          <description>Improvement in acne scarring will be measured by two blinded evaluators both by in-person assessments and by photographic review (digital photography will be used under standardized conditions). A quartile grading scale (1 = 1% to 25%, 2 =26% to 50%, 3 =51% to 75%, 4 = &gt;76% improvement) will be used to measure acne scar improvement. Higher score means better outcome.</description>
          <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>side of face treated</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side of face treated</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2" lower_limit="1" upper_limit="3"/>
                    <measurement group_id="O2" value="2" lower_limit="1" upper_limit="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing Side Effects of the Different Lasers</title>
        <description>measure side effects by patient reported adverse events and blinded physician assessment of adverse effects. Parameters, include erythema, edema, blistering, crusting, scarring, hypopigmentation, and hyperpigmentation, will be graded on a 4-point scale (0 = absent, 1= mild, 2 = moderate, and 3 = severe). Higher score means worse outcome.</description>
        <time_frame>treatment visit 1, treatment visit 2, treatment visit 3, three months after last treatment</time_frame>
        <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
        <group_list>
          <group group_id="O1">
            <title>Fraxel Restore on One Side of the Face</title>
            <description>Fraxel Restore on one side of the face for acne scar correction</description>
          </group>
          <group group_id="O2">
            <title>Fractora on Other Side of the Face</title>
            <description>Fractora on other side of the face for acne scar correction</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Side Effects of the Different Lasers</title>
          <description>measure side effects by patient reported adverse events and blinded physician assessment of adverse effects. Parameters, include erythema, edema, blistering, crusting, scarring, hypopigmentation, and hyperpigmentation, will be graded on a 4-point scale (0 = absent, 1= mild, 2 = moderate, and 3 = severe). Higher score means worse outcome.</description>
          <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>side of face treated</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side of face treated</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparing Intensity of Pain With the Different Lasers</title>
        <description>Patients will also be evaluated the intensity of pain using a visual analogue scale (0 = absence of pain, 10 = most-severe pain). Higher score means worse outcome</description>
        <time_frame>treatment visit 1, treatment visit 2, treatment visit 3</time_frame>
        <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
        <group_list>
          <group group_id="O1">
            <title>Fraxel Restore on One Side of the Face</title>
            <description>Fraxel Restore on one side of the face for acne scar correction</description>
          </group>
          <group group_id="O2">
            <title>Fractora on Other Side of the Face</title>
            <description>Fractora on other side of the face for acne scar correction</description>
          </group>
        </group_list>
        <measure>
          <title>Comparing Intensity of Pain With the Different Lasers</title>
          <description>Patients will also be evaluated the intensity of pain using a visual analogue scale (0 = absence of pain, 10 = most-severe pain). Higher score means worse outcome</description>
          <population>There were 4 participants enrolled and treated, the participants received bilateral facial treatments with Fraxel on one side of the face, and Fractora on the other side of the face</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <units_analyzed>side of face treated</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>side of face treated</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4"/>
                <count group_id="O2" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" lower_limit="2" upper_limit="5"/>
                    <measurement group_id="O2" value="7" lower_limit="6" upper_limit="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>6 months</time_frame>
      <desc>measure adverse events by patient reported adverse events and blinded physician assessment of adverse effects on follow up visits 4 weeks after each treatment as well as at final follow up 3 months after last treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fraxel Restore on One Side of the Face</title>
          <description>Fraxel Restore on one side of the face for acne scar correction</description>
        </group>
        <group group_id="E2">
          <title>Fractora on Other Side of the Face</title>
          <description>Fractora on other side of the face for acne scar correction</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sandeep Saluja</name_or_title>
      <organization>MGH</organization>
      <phone>6466621084</phone>
      <email>sandeep.s.saluja@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

